LABP - Landos Biopharma implements 1-for-10 reverse stock split to regain compliance with Nasdaq requirements
2023-05-25 16:35:35 ET
- Landos Biopharma ( NASDAQ: LABP ) will implement a 1-for-10 reverse stock split of its outstanding shares of common stock, effective on May 25.
- The Company's common stock will trade on a split-adjusted basis starting May 26, under the same trading symbol "LABP."
- As a result of the reverse stock split, the CUSIP number for the Company's common stock will change to 515,069,201.
- The reverse stock split was previously approved by the stockholders at the annual meeting held on May 23, to meet Nasdaq's minimum bid price requirement of $1 per share of common stock.
- ( LABP ) down ~3% after the bell.
- Press Release
For further details see:
Landos Biopharma implements 1-for-10 reverse stock split to regain compliance with Nasdaq requirements